12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-3222: Phase III started

Merck disclosed in its 4Q12 earnings that it began a 64-week, double-blind, placebo-controlled Phase III trial to evaluate 100 and 200 mg subcutaneous MK-3222 at weeks 0 and 4 and then every...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >